Also, we found that the therapeutic effect of the combined administration on MCD diet–induced NASH pathology and fibrosis is similar to that of echinatin or the well-characterized NLRP3 inhibitor MCC950 alone (Figure 7, A and B). Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.